WO2002046218A3 - Treatment of disease by inducing cell apoptosis - Google Patents

Treatment of disease by inducing cell apoptosis Download PDF

Info

Publication number
WO2002046218A3
WO2002046218A3 PCT/US2001/051123 US0151123W WO0246218A3 WO 2002046218 A3 WO2002046218 A3 WO 2002046218A3 US 0151123 W US0151123 W US 0151123W WO 0246218 A3 WO0246218 A3 WO 0246218A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
methods
provides compositions
treatment
activation
Prior art date
Application number
PCT/US2001/051123
Other languages
French (fr)
Other versions
WO2002046218A2 (en
Inventor
Mario Chojkier
Martina Buck
Original Assignee
Univ California
Mario Chojkier
Martina Buck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Mario Chojkier, Martina Buck filed Critical Univ California
Priority to US10/415,325 priority Critical patent/US7402567B2/en
Priority to AU2002241776A priority patent/AU2002241776A1/en
Publication of WO2002046218A2 publication Critical patent/WO2002046218A2/en
Publication of WO2002046218A3 publication Critical patent/WO2002046218A3/en
Priority to US12/166,907 priority patent/US7655472B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates generally to the treatment and prevention of diseases characterized by excess cell proliferation and/or activation. In particular, the present invention provides compositions and methods to suppress the activation and/or proliferation of various cells. In preferred embodiments, the present invention provides compositions and methods to suppress the activation and/or proliferation of mesenchymally derived cells (including, but not limited to hepatic stellate cells), as well as cells with abnormal growth characteristics. In particularly preferred embodiments, the present invention provides compositions and methods to inhibit or eliminate fibrosis. In alternative preferred embodiments, the present invention provides compositions and methods to induce fibrosis.
PCT/US2001/051123 2000-10-27 2001-10-26 Treatment of disease by inducing cell apoptosis WO2002046218A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/415,325 US7402567B2 (en) 2000-10-27 2001-10-26 Treatment of disease by inducing cell apoptosis
AU2002241776A AU2002241776A1 (en) 2000-10-27 2001-10-26 Treatment of disease by inducing cell apoptosis
US12/166,907 US7655472B2 (en) 2000-10-27 2008-07-02 Treatment of disease by inducing cell apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24401800P 2000-10-27 2000-10-27
US60/244,018 2000-10-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/166,907 Continuation US7655472B2 (en) 2000-10-27 2008-07-02 Treatment of disease by inducing cell apoptosis

Publications (2)

Publication Number Publication Date
WO2002046218A2 WO2002046218A2 (en) 2002-06-13
WO2002046218A3 true WO2002046218A3 (en) 2003-10-09

Family

ID=22921059

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/002393 WO2002054938A2 (en) 2000-10-27 2001-10-26 Treatment of disease by inducing cell apoptosis
PCT/US2001/051123 WO2002046218A2 (en) 2000-10-27 2001-10-26 Treatment of disease by inducing cell apoptosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002393 WO2002054938A2 (en) 2000-10-27 2001-10-26 Treatment of disease by inducing cell apoptosis

Country Status (2)

Country Link
AU (1) AU2002241776A1 (en)
WO (2) WO2002054938A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL177989A0 (en) * 2006-09-10 2006-12-31 Yeda Res & Dev Use of transcription factor inhibitor in the manufacture of a medicament
JP7372026B2 (en) * 2015-05-12 2023-10-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Peptide treatment of inflammation and fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215892A (en) * 1989-12-25 1993-06-01 Tadamitsu Kishimoto C/EBP2 gene and recombinant C/EBP2
JPH05192152A (en) * 1991-11-27 1993-08-03 Chuzo Kishimoto Nf-il6beta gene
WO1995003326A1 (en) * 1993-07-20 1995-02-02 The Regents Of The University Of California Regulation of transcription factor, nf-il6/lap

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215892A (en) * 1989-12-25 1993-06-01 Tadamitsu Kishimoto C/EBP2 gene and recombinant C/EBP2
JPH05192152A (en) * 1991-11-27 1993-08-03 Chuzo Kishimoto Nf-il6beta gene
WO1995003326A1 (en) * 1993-07-20 1995-02-02 The Regents Of The University Of California Regulation of transcription factor, nf-il6/lap

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKIRA S ET AL: "A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.", THE EMBO JOURNAL. ENGLAND JUN 1990, vol. 9, no. 6, June 1990 (1990-06-01), pages 1897 - 1906, XP002248618, ISSN: 0261-4189 *
BUCK M ET AL: "C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival.", MOLECULAR CELL. UNITED STATES OCT 2001, vol. 8, no. 4, October 2001 (2001-10-01), pages 807 - 816, XP001157557, ISSN: 1097-2765 *
CAO Z ET AL: "Regulated expression of three C/EBP isoforms during adipose conversion of 3T3 - L1 cells", GENES AND DEVELOPMENT, COLD SPRING HARBOR, NY, US, vol. 5, no. 9, September 1991 (1991-09-01), pages 1538 - 1552, XP002101996, ISSN: 0890-9369 *
DATABASE GENESEQ [online] 21 February 1994 (1994-02-21), "NF-IL6 Beta", retrieved from EBI Database accession no. AAR40801 *
DATABASE WPI Section Ch Week 199335, Derwent World Patents Index; Class B04, AN 1993-277468, XP002248620 *
DESCOMBES P ET AL: "LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcriptional activator protein", GENES AND DEVELOPMENT, COLD SPRING HARBOR, NY, US, vol. 4, no. 9, September 1990 (1990-09-01), pages 1541 - 1551, XP002101997, ISSN: 0890-9369 *
KINOSHITA S ET AL: "A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 15 FEB 1992, vol. 89, no. 4, 15 February 1992 (1992-02-15), pages 1473 - 1476, XP002248617, ISSN: 0027-8424 *
MÜLLER C ET AL: "NF-M (chicken C/EBP beta) induces eosinophilic differentiation and apoptosis in a hematopoietic progenitor cell line.", THE EMBO JOURNAL. ENGLAND 15 DEC 1995, vol. 14, no. 24, 15 December 1995 (1995-12-15), pages 6127 - 6135, XP001149048, ISSN: 0261-4189 *
ZHU M S ET AL: "Expression of exogenous NF-IL6 induces apoptosis in Sp2/0-Ag14 myeloma cells.", DNA AND CELL BIOLOGY. UNITED STATES FEB 1997, vol. 16, no. 2, February 1997 (1997-02-01), pages 127 - 135, XP008017677, ISSN: 1044-5498 *

Also Published As

Publication number Publication date
AU2002241776A1 (en) 2002-06-18
WO2002046218A2 (en) 2002-06-13
WO2002054938A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
WO2005118544A3 (en) Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2002044187A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
IL114641A (en) Pharmaceutical compositions containing dispersible fluoxetine
EP1478322A4 (en) Beta-2'-OR 3'-HALONUCLEOSIDES
NO20055130L (en) Aminocyclohexyl ether compounds and their use
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2006026570A3 (en) Use of stem cells to generate inner ear cells
TW200714277A (en) Methods and compositions for altering cell fuction
GB0111186D0 (en) Novel compounds
UA86345C2 (en) Normal;heading 1;heading 2;USE OF OSTEOPROTEGERIN FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS
WO2005000248A3 (en) Compositions and methods for skin conditioning
AU3227700A (en) Skin sanitizing compositions
WO2004093995A3 (en) Use of antioxidants to treat bone loss disorders
MX2008005409A (en) Modulation of 11beta-hydroxysteroid dehydrogenase 1 expression for the treatment of ocular diseases.
MXPA04001256A (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof.
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
WO2004052294A3 (en) Compositions and methods related to lipid:emodin formulations
RS20060154A (en) Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
WO2002046218A3 (en) Treatment of disease by inducing cell apoptosis
WO2003072031A3 (en) Treatment of disease by inducing cell apoptosis
AU2003269871A1 (en) Radiosensitizer composition containing n-acetylphytosphingosine analogs and n,n-dimethyl-phytosphingosine analogs as the active ingredients
WO2002059281A3 (en) High level cytokine production with enhanced cell viability
WO2005089772A3 (en) Prevention of loss of tight cell junctions using carbohydrate-containing compositions
WO2002051404A8 (en) Compositions for oral use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10415325

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP